Endocrinology Search
Endocrinology Endocrinology
diabetes%20mellitus
DIABETES MELLITUS
Diabetes mellitus (DM) is a heterogenous metabolic disorder characterized by the presence of hyperglycemia with carbohydrate, protein and fat metabolism disturbance which results from defects in either insulin secretion or action.
Patients with DM usually present with polyuria, polydipsia and unexplained weight loss.
Type 1 DM is caused by beta cell destruction which leads to complete insulin deficiency. It may be immune mediated or idiopathic.
Patients may present with ketoacidosis or acute onset of hyperglycemia while other patients may resemble type 2 DM or symptoms of other autoimmune disorders.
Type 2 DM is the most common form of diabetes. It is secondary to defect in insulin secretion concomitant with insulin resistance.
Majority of patients are asymptomatic. Ketoacidosis is uncommon and is usually secondary to stress (eg infection).

Diabetes Mellitus Drug Information

Drug Information

Indication: NIDDM (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to co...

Indication: Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy; a...

Glyxambi
empagliflozin + linagliptin

Indication: Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM when treatment w/ both empag...

Indication: Type 2 DM as monotherapy in adults inadequately controlled by diet & exercise alone & for whom metform...

Indication: Adjunct to diet & exercise to improve glycaemic control in adult patients w/ type 2 DM when treatment w/ b...

Lusefi
luseogliflozin hydrate

Indication: Monotherapy or add-on combination therapy w/ sulfonylurea in adult patients w/ type 2 DM.

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Qtern
dapagliflozin + saxagliptin

Indication: Adults ≥18 yr w/ type 2 DM inadequately controlled on metformin alone or when already treated w/ fixed-dose...

Indication: Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM.

Indication: Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM.

1  /  18
1  /  18
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Artificially sweetened, sugar-free drinks a good substitute for sugary drinks to shed pounds
3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Cabotegravir superior to TDF/FTC for HIV prevention
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Once-a-month prevention pill succeeds in malaria-endemic areas
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.